Shares of Resverlogix Corp. (TSE:RVX – Get Free Report) hit a new 52-week low on Friday . The stock traded as low as C$0.05 and last traded at C$0.05, with a volume of 216634 shares. The stock had previously closed at C$0.05.
Resverlogix Price Performance
The company’s 50-day moving average is C$0.05 and its 200-day moving average is C$0.06. The firm has a market capitalization of C$8.91 million, a price-to-earnings ratio of -2.23 and a beta of 0.71. The company has a debt-to-equity ratio of -10.95, a current ratio of 0.13 and a quick ratio of 0.04.
About Resverlogix
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
Featured Articles
- Five stocks we like better than Resverlogix
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Manufacturing Stocks Investing
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- 3 Grocery Stocks That Are Proving They Are Still Essential
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
